Douglas Lane & Associates LLC Reduces Stock Holdings in GSK PLC Sponsored ADR $GSK

Key Points

• Douglas Lane & Associates reduced its GSK holdings by 20.8% in the third quarter, selling 196,946 shares and retaining 749,690 shares valued at approximately $36.1 million.
• Analyst sentiment is mixed but leans toward “Hold”: GSK has one Strong Buy, two Buy, seven Hold and two Sell ratings, with an average price target of $61.
• GSK reported quarterly EPS of $1.36, exceeding estimates of $1.27, while revenue rose 5.3% year over year to $11.14 billion. The company also increased its quarterly dividend to $0.4515 per share, implying an annualized yield of about 3.9%.

Douglas Lane & Associates LLC lessened its holdings in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 20.8% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 749,690 shares of the pharmaceutical company's stock after selling 196,946 shares during the quarter. Douglas Lane & Associates LLC's holdings in GSK were worth $36,113,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in GSK. Security National Bank of SO Dak purchased a new position in shares of GSK during the second quarter valued at approximately $38,000. Trust Co. of Vermont bought a new stake in shares of GSK in the 2nd quarter worth approximately $54,000. Philadelphia Investment Partners LLC purchased a new stake in shares of GSK in the 2nd quarter worth approximately $70,000. Ancora Advisors LLC purchased a new stake in shares of GSK in the 2nd quarter worth approximately $71,000. Finally, Bogart Wealth LLC increased its position in GSK by 15.3% during the 1st quarter. Bogart Wealth LLC now owns 1,508 shares of the pharmaceutical company's stock valued at $83,000 after buying an additional 200 shares in the last quarter. Institutional investors own 15.74% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on GSK shares. Jefferies Financial Group upgraded GSK to a "strong-buy" rating in a research note on Friday, July 17th. Citigroup started coverage on GSK in a research note on Friday, July 24th. They issued a "neutral" rating on the stock. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of GSK in a report on Thursday, July 30th. Wall Street Zen cut shares of GSK from a "buy" rating to a "hold" rating in a research note on Saturday, August 1st. Finally, Weiss Ratings downgraded shares of GSK from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, seven have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $61.00.

GSK Stock Performance

GSK traded up $0.09 during midday trading on Friday, hitting $46.62. 5,658,264 shares of the company traded hands, compared to its average volume of 4,412,995. The company's 50-day moving average is $50.12 and its 200 day moving average is $51.87. The company has a quick ratio of 0.52, a current ratio of 0.82 and a debt-to-equity ratio of 0.81. The firm has a market capitalization of $94.31 billion, a PE ratio of 14.58, a price-to-earnings-growth ratio of 2.11 and a beta of 0.33. GSK PLC Sponsored ADR has a 52 week low of $42.85 and a 52 week high of $61.69.

GSK (NYSE:GSK - Get Free Report) last announced its quarterly earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 EPS for the quarter, topping analysts' consensus estimates of $1.27 by $0.09. GSK had a net margin of 14.56% and a return on equity of 43.23%. The firm had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.02 billion. During the same period in the previous year, the business posted $0.47 earnings per share. The business's revenue for the quarter was up 5.3% on a year-over-year basis. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. On average, research analysts expect that GSK PLC Sponsored ADR will post 4.79 EPS for the current year.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, October 8th. Shareholders of record on Friday, August 14th were paid a dividend of $0.4515 per share. The ex-dividend date was Friday, August 14th. This represents a $1.81 dividend on an annualized basis and a yield of 3.9%. This is a boost from GSK's previous quarterly dividend of $0.44. GSK's dividend payout ratio (DPR) is presently 55.31%.

GSK Profile

GSK plc is a global biopharmaceutical company headquartered in Brentford, England. The company develops and commercializes medicines and vaccines, with research and commercial activities focused on infectious diseases, respiratory conditions, immunology, oncology and HIV. Its products are distributed across markets worldwide through healthcare providers, public health systems and pharmacies.

GSK's portfolio includes vaccines such as Shingrix for shingles and Arexvy for respiratory syncytial virus (RSV), as well as specialty medicines including Trelegy for chronic respiratory disease and Nucala for severe asthma and related inflammatory conditions.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK PLC Sponsored ADR (NYSE:GSK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.